Evidence map›Paper›PMID 38856768›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2024

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.

Oscar Hou In Chou, Vinod Kumar Chauhan, Cheuk To Skylar Chung, Lei Lu, Teddy Tai Loy Lee, Zita Man Wai Ng, Karin Kai Wing Wang, Sharen Lee, Haipeng Liu, Ronald Ting Kai Pang and 4 more

Erratum issuedAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Type 2 diabetes in patients undergoing gastric cancer surgery: areas requiring disease-specific glycemic management.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Oscar Hou In Chou *Division of Clinical Pharmacology, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Vinod Kumar Chauhan *Institute of Biomedical Engineering, Department of Engendering Science, University of Oxford, Oxford, UK.
Cheuk To Skylar ChungDiabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China.
Lei LuInstitute of Biomedical Engineering, Department of Engendering Science, University of Oxford, Oxford, UK.
Teddy Tai Loy LeeDiabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China.
Zita Man Wai NgDiabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China.
Karin Kai Wing WangDiabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China.
Sharen LeeDiabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China.
Haipeng LiuResearch Centre for Intelligent Healthcare, Coventry University, Coventry, UK.
Ronald Ting Kai PangSchool of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.
Apichat KaewdechDivision of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Bernard Man Yung CheungDivision of Clinical Pharmacology, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Gary TseSchool of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.ORCID http://orcid.org/0000-0001-5510-1253
Jiandong ZhouDepartment of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. jdzhou@hku.hk.

Funding

Hong Kong Metropolitan University Research Impact Fund RIF/2022/2.2
6 · The paper itself

Abstract

objectiveTo compare the risks of gastric cancer and other gastric diseases in patients with type-2 diabetes mellitus (T2DM) exposed to sodium-glucose cotransporter 2 inhibitors (SGLT2I), dipeptidyl peptidase-4 inhibitors (DPP4I) or glucagon-like peptide-1 receptor agonists (GLP1a).

designThis was a population-based cohort study of prospectively collected data on patients with T2DM prescribed SGLT2I, DPP4I or GLP1a between January 1st 2015 and December 31st 2020 from Hong Kong. The outcomes were new-onset gastric cancer, peptic ulcer (PU), acute gastritis, non-acute gastritis, and gastroesophageal reflux disease (GERD). Propensity score matching (1:1) using the nearest neighbour search was performed, and multivariable Cox regression was applied. A three-arm comparison between SGLT2I, DPP4I and GLP1a was conducted using propensity scores with inverse probability of treatment weighting.

resultsA total of 62,858 patients (median age: 62.2 years old [SD: 12.8]; 55.93% males; SGLT2I: n = 23,442; DPP4I: n = 39,416) were included. In the matched cohort, the incidence of gastric cancer was lower in SGLT2I (Incidence rate per 1000 person-year, IR: 0.32; 95% confidence interval, CI 0.23-0.43) than in DPP4I (IR per 1000 person-year: 1.22; CI 1.03-1.42) users. Multivariable Cox regression found that SGLT2I use was associated with lower risks of gastric cancer (HR 0.30; 95% CI 0.19-0.48), PU, acute gastritis, non-acute gastritis, and GERD (p < 0.05) compared to DPP4I use. In the three-arm analysis, GLP1a use was associated with higher risks of gastric cancer and GERD compared to SGLT2I use.

conclusionsThe use of SGLT2I was associated with lower risks of new-onset gastric cancer, PU, acute gastritis, non-acute gastritis, and GERD after matching and adjustments compared to DPP4I use. SGLT2I use was associated with lower risks of GERD and gastric cancer compared to GLP1a use.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsStomach NeoplasmsAgedCohort StudiesFemaleHong KongHumansHypoglycemic AgentsMaleMiddle AgedStomach DiseasesDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsDipeptidyl peptidase-4 inhibitors (DPP4I)Gastric cancerGastritisGlucagon-like peptide-1 receptor agonist (GLP1a)Peptic ulcerSodium-glucose cotransporter 2 inhibitors (SGLT2I)

Identifiers

PMID38856768
PMCPMC11335951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.